Synapsoft logo
AI Insights from Disclosures
Searching...
Curocell Inc. 372320
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Curocell Inc. was founded in 2016 with the goal of improving the cancer treatment efficacy of CAR-T therapies sold in the global market, and is a cell and gene therapy developer with multiple new drug pipelines, including a CD19 CAR-T therapy that was the first in Korea to receive clinical trial approval for a next-generation CAR-T therapy from the Ministry of Food and Drug Safety, as well as hematologic cancer CAR-T, solid tumor CAR-T, and allogeneic CAR-T therapies. The company is composed of experts in new drug research, development, and production, including basic biology scientists, process development specialists, analytical method development specialists, and clinical development and production technology specialists, and based on this, it has secured platform technology for discovering and developing next-generation CAR-T therapies as well as its own proprietary manufacturing process and analytical technologies.
Representative Director Kim Geonsu
Founded December 1, 2016
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 13111-0466283
Business number 148-88-00557
Phone Number 042-863-3698
Fax Number 0428633695
Website curocellbtx.com
Company Address 11 Gukjegwahak 16-ro, Yuseong-gu, Daejeon
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant